Researchers reported the development of carHLH in 14·8% of paediatric patients and young adults treated with CD19-specific CAR T-cell therapy with carHLH, occurring most commonly in those with high disease burden.
[British Journal of Haematology]
6445218
{6445218:KL35AHJ7}
apa
50
1
164686
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
